세계의 EV 기반 액체생검 시장 : 제공, 워크플로우, 샘플 유형, 최종사용자, 기술, 지역별 분석, 경쟁 구도 - 분석과 예측(2023-2032년)

“Global EV-Based Liquid Biopsy Market to Reach $455.53 Million by 2032.”

Global EV-Based Liquid Biopsy Market Overview

The global EV-based liquid biopsy market was valued at $78.22 million in 2022 and is anticipated to reach $455.53 million by 2032, witnessing a CAGR of 19.73% during the forecast period 2023-2032. The global EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.

Market Lifecycle Stage

The global EV-based liquid biopsy market is in progressing phase, which can be attributed to the increase in academic research and approval of products in the market. Furthermore, the expanding applications of EV-based liquid biopsy in personalized medicine and precision oncology are projected to drive further market expansion.

Impact

The adoption of EV-based liquid biopsy has revolutionized disease diagnosis and monitoring, offering numerous benefits over traditional biopsy methods. Its non-invasiveness, real-time monitoring capabilities, and potential for early disease detection have transformed the field of healthcare diagnostics. By providing a less invasive and more accessible method for detecting and monitoring diseases, particularly cancer, EV-based liquid biopsy has improved patient experiences, reduced healthcare costs, and enhanced overall healthcare outcomes. In addition, the entry of several established players, such as Thermo Fisher Scientific Inc., QIAGEN N.V., and Bio-Techne Corporation, is expected to aid the market growth.

Furthermore, the growth of the EV-based liquid biopsy market has stimulated research and development activities, fostered collaborations between industry players and academic institutions, and generated economic opportunities.

Market Segmentation:

Segmentation 1: by Offering

• Kits and Assays
• Services
• Instruments

Kits and Assays Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Offering)

Based on offering, the kits and assays segment dominated the global EV-based liquid biopsy market in FY2022. The increasing adoption of isolation kits, assays, and accessories contributed to the prominence of this segment. Various exosome and EV isolation kits are being used to carry out several procedures and liquid biopsy tests.

Segmentation 2: by Technology

• Isolation
• Analysis

Isolation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Technology)

Based on technology, the isolation segment dominated the global EV-based liquid biopsy market in FY2022. Under isolation technology, precipitation emerged as the most common technology used.

Segmentation 3: by Workflow

• Sample Preparation
• Sequencing
• Data Analysis

Sample Preparation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Workflow)

Based on workflow, the EV-based liquid biopsy market was dominated by the sample preparation segment in FY2022. The sample preparation or pre-analytical phase in the EV-based liquid biopsy workflow includes specimen collection, stabilization, transport, enrichment, processing, isolation, and quality assessment of the analyte.

Segmentation 4: by End User

• Academic and Research Institutes
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies

Academic and Research Institutes Segment to Dominate the Global EV-Based Liquid Biopsy Market (by End User)

Based on end user, academic and research segment accounted for the largest share of the global EV-based liquid biopsy market in FY2022. Academic and research institutes play a vital role in the adoption of EV-based liquid biopsy methods, serving as essential facilities for both companies and independent academic research. These institutions are primarily engaged in research activities aimed at identifying biomarkers, developing drugs, and conducting cell analysis to acquire targets.

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Latin America and Middle East
• Rest-of-the-World

In 2022, the North America region dominated the global EV-based liquid biopsy market, and it is expected to hold its dominance throughout the forecast period 2023-2032. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 21.64% in the market during the forecast period 2023-2032.

Demand - Drivers, Restraints, and Opportunities

Market Demand Drivers:

• Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
• Amplified Funding and Dedicated Research Efforts
• Increasing Prevalence of Cancers

Market Restraints:

• Lack of Standardized EV Isolation and Characterization Protocols
• Lack of Precise EV Subtype Classification and Biomarkers Validation

Market Opportunities:

• Advancements in EV-Based Liquid Biopsy Technologies
• Development of New EV-Based Biomarkers
• Approved Products in the Market

How can this report add value to an organization?

• Workflow/Innovation Strategy: The EV-based liquid biopsy market (by offering) has been segmented into kits and assays, instruments, and services. Moreover, the study provides the reader with a detailed understanding of the different types of technologies, end-users, and sample types used in these tests.

• Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of Evs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.

• Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

EV-based liquid biopsy refers to the use of extracellular vesicles (Evs) as a non-invasive diagnostic tool for detecting and monitoring various diseases, including cancer. The global EV-based liquid biopsy market has experienced substantial growth driven by technological advancements, rising demand for non-invasive diagnostics, and the global increase in cancer prevalence.

Key Companies Profiled:

Table of Contents

1 Definition

• 1.1 Inclusion and Exclusion Criteria

2 Research Scope

• 2.1 Target Audience
• 2.2 Key Questions Answered in the Report:

3 Research Methodology

• 3.1 Global EV-Based Liquid Biopsy Market: Research Methodology
• 3.2 Primary Data Sources
• 3.3 Secondary Data Sources
• 3.4 Market Estimation Model
• 3.5 Criteria for Company Profiling

4 Markets Overview

• 4.1 Market Introduction
• 4.2 Current and Future State of EV-Based Liquid Biopsy in Industries
• 4.3 Current Market Size and Growth Potential, $Million, 2022-2032
• 4.4 COVID-19 Impact on Global EV-based Liquid Biopsy Market
  • 4.4.1 Impact on Operations
  • 4.4.2 COVID-19 Impact: Current Scenario of the Market

5 Methods of EV Isolation and Analysis

• 5.1 Overview
  • 5.1.1 Evs Introduction
• 5.2 Isolation Methods
  • 5.2.1 EV Isolation Techniques Utilizing Ultracentrifugation Methods
    • 5.2.1.1 Differential Ultracentrifugation
    • 5.2.1.2 Density Gradient Centrifugation
    • 5.2.1.3 Moving Zone or Rate-Zonal Centrifugation
    • 5.2.1.4 Isopycnic Centrifugation
  • 5.2.2 EV Isolation Techniques Utilizing Size-Based Methods
    • 5.2.2.1 Ultrafiltration
    • 5.2.2.2 Sequential Filtration
    • 5.2.2.3 Size Exclusion Chromatography (SEC)
    • 5.2.2.4 Flow Field-Flow Fractionation (FFFF)
    • 5.2.2.5 Hydrostatic Filtration Dialysis (HFD)
  • 5.2.3 EV Isolation Techniques Utilizing Immunoaffinity Methods
    • 5.2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
    • 5.2.3.2 Magneto-Immunoprecipitation
  • 5.2.4 EV Isolation Techniques Utilizing Precipitation Methods
    • 5.2.4.1 Polyethylene Glycol (PEG) Precipitation
    • 5.2.4.2 Lectin Induced Agglutination
  • 5.2.5 EV Isolation Techniques Utilizing Microfluidic Technology
  • 5.2.6 EV Isolation Techniques Utilizing Commercial Kits
  • 5.2.7 Advantages and Disadvantages of the EV Isolation Methods
  • 5.2.8 Novel Approaches for Exosome Isolation
• 5.3 Analysis Methods
  • 5.3.1 Advantages and Disadvantages of Analysis Methods for Evs

6 Industry Insights

• 6.1 Overview
• 6.2 Legal Requirements in the U.S.
• 6.3 Legal Requirements and Frameworks in Europe
• 6.4 Legal Requirements and Frameworks in Asia-Pacific
• 6.5 Reimbursement Scenario

7 Market Dynamics

• 7.1 Overview
• 7.2 Impact Analysis
• 7.3 Market Drivers
  • 7.3.1 Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
  • 7.3.2 Amplified Funding and Dedicated Research Efforts
  • 7.3.3 Rising Prevalence of Cancers
• 7.4 Market Restraints
  • 7.4.1 Lack of Standardized EV Isolation and Characterization Protocols
  • 7.4.2 Lack of Precise EV Subtype Classification and Biomarkers Validation
• 7.5 Market Opportunities
  • 7.5.1 Advancements in EV-Based Liquid Biopsy Technologies
  • 7.5.2 Development of New EV-Based Biomarkers
  • 7.5.3 Approved Products in the Market

8 Competitive Landscape

• 8.1 Competitive Landscape Overview
  • 8.1.1 Key Developments
  • 8.1.2 Product Launches and Expansion Activities
  • 8.1.3 Merger and Acquisition Activities
  • 8.1.4 Synergistic Activities
  • 8.1.5 License and Agreement Activities
  • 8.1.6 Other Activities
• 8.2 Market Share Analysis (2022)
• 8.3 Growth-Share Analysis (2021-2022)
  • 8.3.1 Growth-Share Analysis (by Company)

9 Global EV-Based Liquid Biopsy Market (by Offering),$Million, 2022-2032

• 9.1 Overview
• 9.2 Kits and Assays
• 9.3 Services
• 9.4 Instruments

10 Global EV-Based Liquid Biopsy Market (by Workflow), $Million, 2022-2032

• 10.1 Overview
  • 10.1.1 Sample Preparation
  • 10.1.2 Sequencing
  • 10.1.3 Data Analysis

11 Global EV-Based Liquid Biopsy Market (by Technology), $Million, 2022-2032

• 11.1 Overview
• 11.2 Isolation Technologies
  • 11.2.1 Precipitation
  • 11.2.2 Ultracentrifugation
  • 11.2.3 Chromatography
• 11.3 Analysis Technologies
  • 11.3.1 NGS
  • 11.3.2 PCR
  • 11.3.3 Flow Cytometry

12 Global EV-Based Liquid Biopsy Market (by Sample Type), $Million, 2022-2032

• 12.1 Overview
  • 12.1.1 Blood
  • 12.1.2 Urine
  • 12.1.3 Saliva
  • 12.1.4 Other Biofluids

13 Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022-2032

• 13.1 Overview
• 13.2 Academic and Research Institutes
• 13.3 Pharmaceutical and Biotechnology Companies
• 13.4 Clinical Laboratories

14 Global EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032

• 14.1 Overview
• 14.2 North America
  • 14.2.1 U.S.
  • 14.2.2 Canada
• 14.3 Europe
  • 14.3.1 Germany
  • 14.3.2 U.K.
  • 14.3.3 France
  • 14.3.4 Italy
  • 14.3.5 Spain
  • 14.3.6 Rest-of-Europe
• 14.4 Asia-Pacific
  • 14.4.1 China
  • 14.4.2 Japan
  • 14.4.3 India
  • 14.4.4 South Korea
  • 14.4.5 Australia
  • 14.4.6 Singapore
  • 14.4.7 Rest-of-Asia-Pacific
• 14.5 Latin America and Middle East
  • 14.5.1 Brazil
  • 14.5.2 Mexico
  • 14.5.3 Saudi Arabia
  • 14.5.4 Rest-of-Latin America and Middle East
• 14.6 Rest-of-the-World

15 Company Profiles

• 15.1 Company Overview
  • 15.1.1 Abcam plc
    • 15.1.1.1 Company Overview
    • 15.1.1.2 Role of Abcam plc in the Global EV-Based Liquid Biopsy Market
    • 15.1.1.3 Major Products: Key Specifications
    • 15.1.1.4 Key Competitors
    • 15.1.1.5 Analyst Perspective
  • 15.1.2 Bio-Techne Corporation
    • 15.1.2.1 Company Overview
    • 15.1.2.2 Role of Bio-Techne Corporation in the Global EV-Based Liquid Biopsy Market
    • 15.1.2.3 Major Products: Key Specifications
    • 15.1.2.4 Key Competitors
    • 15.1.2.5 Analyst Perspective
  • 15.1.3 Horiba Ltd.
    • 15.1.3.1 Company Overview
    • 15.1.3.2 Role of Horiba Ltd. in the Global EV-Based Liquid Biopsy Market
    • 15.1.3.3 Major Products: Key Specifications
    • 15.1.3.4 Key Competitors
    • 15.1.3.5 Analyst Perspective
  • 15.1.4 Qiagen N.V.
    • 15.1.4.1 Company Overview
    • 15.1.4.2 Role of Qiagen N.V. in the Global EV-Based Liquid Biopsy Market
    • 15.1.4.3 Major Products: Key Specifications
    • 15.1.4.4 Key Competitors
    • 15.1.4.5 Analyst Perspective
  • 15.1.5 Thermo Fisher Scientific, Inc.
    • 15.1.5.1 Company Overview
    • 15.1.5.2 Role of Thermo Fisher Scientific, Inc. in the Global EV-Based Liquid Biopsy Market
    • 15.1.5.3 Major Products: Key Specifications
    • 15.1.5.4 Key Competitors
    • 15.1.5.5 Analyst Perspective
  • 15.1.6 Malvern Panalytical Ltd
    • 15.1.6.1 Company Overview
    • 15.1.6.2 Role of Malvern Panalytical Ltd in the Global EV-Based Liquid Biopsy Market
    • 15.1.6.3 Major Products: Key Specifications
    • 15.1.6.4 Key Competitors
    • 15.1.6.5 Analyst Perspective
  • 15.1.7 Lonza Group AG
    • 15.1.7.1 Company Overview
    • 15.1.7.2 Role of Lonza Group AG in the Global EV-Based Liquid Biopsy Market
    • 15.1.7.3 Major Products: Key Specifications
    • 15.1.7.4 Key Competitors
    • 15.1.7.5 Analyst Perspective
  • 15.1.8 Revvity, Inc. (PerkinElmer, Inc.)
    • 15.1.8.1 Company Overview
    • 15.1.8.2 Role of Revvity, Inc. (PerkinElmer Inc.) in the Global EV-Based Liquid Biopsy Market
    • 15.1.8.3 Major Products: Key Specifications
    • 15.1.8.4 Key Competitors
    • 15.1.8.5 Analyst Perspective
  • 15.1.9 Takara Bio Inc.
    • 15.1.9.1 Company Overview
    • 15.1.9.2 Role of Takara Bio Inc. in the Global EV-Based Liquid Biopsy Market
    • 15.1.9.3 Major Products: Key Specifications
    • 15.1.9.4 Key Competitors
    • 15.1.9.5 Analyst Perspective
  • 15.1.10 Norgen Biotek Corp.
    • 15.1.10.1 Company Overview
    • 15.1.10.2 Role of Norgen Biotek Corp. in the Global EV-Based Liquid Biopsy Market
    • 15.1.10.3 Major Products: Key Specifications
    • 15.1.10.4 Key Competitors
    • 15.1.10.5 Analyst Perspective
  • 15.1.11 Emerging Companies
    • 15.1.11.1 Mursla Bio
    • 15.1.11.2 Nanostics Inc.
    • 15.1.11.3 Mercy BioAnalytics, Inc.
    • 15.1.11.4 Clara Diagnostics, Inc. (Clara Biotech)